MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$10,309K
EPS
-$0.11
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
-
-
0
190
Research and development
6,748
7,317
10,891
22,130
General and administrative
4,133
4,119
3,905
4,805
Total operating expenses
10,881
11,436
14,796
26,935
Loss from operations
-10,881
-11,436
-14,796
-26,745
Total other income (expense), net
571
644
832
999
Consolidated net loss
-10,310
-10,792
-13,964
-25,746
Net loss attributable to noncontrolling interest in pangu biopharma limited
-1
-1
-1
-2
Net loss attributable to atyr pharma, inc
-10,309
-10,791
-13,963
-25,744
Basic EPS
-0.11
-0.11
-0.142
-0.26
Diluted EPS
-0.11
-0.11
-0.142
-0.26
Basic Average Shares
98,069,915
98,043,839
98,182,534
97,153,541
Diluted Average Shares
98,069,915
98,043,839
98,182,534
97,153,541
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
attributable to atyr pharma,...
-$10,309K
(47.22%↑ Y/Y)
Net loss
attributable to...
-$1K
(0.00%↑ Y/Y)
Consolidated net loss
-$10,310K
(47.21%↑ Y/Y)
Total other income
(expense), net
$571K
(-26.89%↓ Y/Y)
Loss from operations
-$10,881K
(46.43%↑ Y/Y)
Total operating
expenses
$10,881K
(-46.43%↓ Y/Y)
Research and development
$6,748K
(-56.14%↓ Y/Y)
General and
administrative
$4,133K
(-16.15%↓ Y/Y)
Buy us a coffee
aTYR PHARMA INC (ATYR)
aTYR PHARMA INC (ATYR)